This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Snap (SNAP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Snap (SNAP) delivered earnings and revenue surprises of 150% and 7.72%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Alkami (ALKT) Surges 5.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alkami (ALKT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alkami (ALKT) Soars 5.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alkami (ALKT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alkami Technology (ALKT) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Alkami Technology (ALKT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alkami (ALKT) delivered earnings and revenue surprises of 50% and 4.49%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Market: NVIDIA, Oracle, Celsius in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
What Makes Alkami Technology (ALKT) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Alkami Technology (ALKT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights Carnival, Amylyx Pharmaceuticals and Alkami Technology
by Zacks Equity Research
Carnival, Amylyx Pharmaceuticals and Alkami Technology have been highlighted in this Screen of The Week article.
3 Stocks Worth a Buy for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Some of the notable companies to have witnessed solid earnings acceleration as of now are Carnival (CCL), Amylyx Pharmaceuticals (AMLX) and Alkami Technology (ALKT).
Here's Why Alkami Technology (ALKT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Alkami Technology (ALKT) have what it takes to be a top stock pick for momentum investors? Let's find out.